Honasa Consumer to acquire 58% in Fluence Pharma for about Rs 135 Cr

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

HONASA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹420.00

prior close

₹429.05

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%-1.4% vs market

Personal Care peers, median of 13sector-0.5%-0.7% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Smallcap 250 and 0.7 pts less than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-2.6

15m

-3.9

30m

-5.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2+0.2-1.4-0.5-0.7

Next day

-0.7-0.2-0.5-0.8+0.1

+5.8-0.7+6.5+0.9+4.9

+9.0-0.2+9.2-0.1+9.1

+11.0+0.3+10.6+3.2+7.7

+11.3+1.3+10.0+3.7+7.6

+11.7+1.9+9.8+3.2+8.5

15d

+11.6+2.0+9.6-0.5+12.1

+6.7-0.8+7.6-0.3+7.1

+16.9+3.5+13.4-5.3+22.2

+13.1+2.3+10.8-8.3+21.4

UpDownMarket · Nifty Smallcap 250Sector · Personal Care peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Honasa Consumer (Mamaearth) board approved acquiring 58% stake in Fluence Pharma, a dermatologist-led nutraceuticals company, for an enterprise value of about Rs 135 Cr (around 3.4x FY26 revenue, 15x EBITDA). Remaining 42% to be bought in two tranches over 5-7 years. Fluence had FY26 revenue of about Rs 40 Cr with 20% plus EBITDA margin. Honasa will also incorporate wholly owned subsidiary Honasa Health for B2C nutraceuticals. Deal expected to close in 8 weeks. Aims to build a Rs 500 Cr nutraceuticals franchise.

Likely market impact

Entry into fast-growing nutraceuticals category via a Rs 135 Cr cash deal; positive for long-term growth but adds integration risk.